ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer

(2017) Satoshi Hori et al.   INTERNATIONAL JOURNAL OF CANCER

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

(2017) Pasi A. Jänne et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer

(2017) Angela M. Krebs et al.   NATURE CELL BIOLOGY

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sef Regulates Epithelial-Mesenchymal Transition in Breast Cancer Cells

(2016) Qing He et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

ZEB1 drives epithelial-to-mesenchymal transition in lung cancer

(2016) Jill E. Larsen et al.   JOURNAL OF CLINICAL INVESTIGATION

A combinatorial strategy for treating KRAS-mutant lung cancer

(2016) Eusebio Manchado et al.   NATURE

ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis

(2016) D H Peng et al.   ONCOGENE

A genetic cell context-dependent role for ZEB1 in lung cancer

(2016) Ting Zhang et al.   Nature Communications

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer

(2016) H. Kitai et al.   Cancer Discovery

In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer

(2016) Alessandro Carugo et al.   Cell Reports

The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL

(2016) Christin Ungewiss et al.   Scientific Reports

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†

(2015) G. R. Blumenschein et al.   ANNALS OF ONCOLOGY

An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2

(2015) R. J. G. Cardnell et al.   CLINICAL CANCER RESEARCH

ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

(2015) S. Meidhof et al.   EMBO Molecular Medicine

Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis

(2015) Zhen Zhao et al.   NATURE GENETICS

The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers

(2015) S T Kundu et al.   ONCOGENE

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

(2014) Piro Lito et al.   CANCER CELL

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

(2014) Ho-June Lee et al.   CANCER CELL

Raf-interactome in tuning the complexity and diversity of Raf function

(2014) Su An et al.   FEBS Journal

ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism

(2014) Yanan Yang et al.   JOURNAL OF CLINICAL INVESTIGATION

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

The Pitx2:miR-200c/141:noggin pathway regulates Bmp signaling and ameloblast differentiation

(2013) H. Cao et al.   DEVELOPMENT

Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators

(2013) Yuanxiang Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression

(2012) Young-Ho Ahn et al.   JOURNAL OF CLINICAL INVESTIGATION

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

(2012) Zhao Chen et al.   NATURE

A Resource for the Conditional Ablation of microRNAs in the Mouse

(2012) Chong Yon Park et al.   Cell Reports

Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer

(2011) Ali Aghdassi et al.   GUT

An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition

(2011) Philip A. Gregory et al.   MOLECULAR BIOLOGY OF THE CELL

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induction of E-Cadherin in Lung Cancer and Interaction with Growth Suppression by Histone Deacetylase Inhibition

(2010) Masatoshi Kakihana et al.   Journal of Thoracic Oncology

A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers

(2010) Bryan T. Hennessy et al.   Clinical Proteomics

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

Modelling oncogenic Ras/Raf signalling in the mouse

(2009) Florian A Karreth et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts

(2009) Nils Blüthgen et al.   FEBS Journal

Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression

(2009) D. L. Gibbons et al.   GENES & DEVELOPMENT

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

(2009) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs

(2009) Ulrich Wellner et al.   NATURE CELL BIOLOGY

Statistical methods for analysis of high-throughput RNA interference screens

(2009) Amanda Birmingham et al.   NATURE METHODS

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

(2009) Michel DuPage et al.   Nature Protocols

The Transcriptional Repressor ZEB1 Promotes Metastasis and Loss of Cell Polarity in Cancer

(2008) S. Spaderna et al.   CANCER RESEARCH

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

(2008) Philip A. Gregory et al.   NATURE CELL BIOLOGY

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

hSef potentiates EGF-mediated MAPK signaling through affecting EGFR trafficking and degradation

(2007) Yongming Ren et al.   CELLULAR SIGNALLING